Viracta Therapeutics, Inc., a clinical-stage precision oncology company dedicated to treating and preventing virus-associated cancers that affect patients globally, has terminated its employees and is winding down its operations. The company is also actively exploring potential strategic alternatives for its development programs. The board of directors has appointed Craig R. Jalbert, a seasoned accounting professional with over 30 years of experience, as the Company’s CEO, President, CFO, Tre...